AbbVie $100 Billion Deal With Trump
AbbVie $100 Billion Deal with Trump trades Medicaid price concessions and tariff relief for a decade of U.S. investment, pressuring near-term margins.
KEY TAKEAWAYS
- Agreement swaps near-term pricing concessions for a $100.0 billion U.S. investment pledge over the next decade.
- Deal grants a three-year tariff exemption plus relief from future pricing mandates and expands TrumpRx access.
- Company said the commitments are forward-looking and subject to regulatory, trade and execution risks.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
AbbVie Inc. on Jan. 12, 2026 announced a voluntary three-year agreement with the Trump administration that commits the company to a $100 billion U.S. investment pledge over the next decade. In exchange, AbbVie will lower Medicaid drug prices, expand access through TrumpRx, and receive exemptions from tariffs and future pricing mandates.
Deal Terms, Pricing Concessions, and Investment Commitment
The agreement includes a three-year tariff exemption and relief from future pricing mandates. AbbVie framed the deal as a trade-off, exchanging near-term pricing concessions and broader patient access commitments for policy protections and a decade-long domestic investment pledge. The company said the commitments are forward-looking and subject to risks such as regulatory changes, trade disputes, and its ability to realize benefits.
AbbVie agreed to offer low prices in Medicaid and expand affordable direct-to-patient offerings through TrumpRx for medicines used by millions, including ALPHAGAN, COMBIGAN, HUMIRA, and SYNTHROID. The company said the deal addresses all four of the President’s drug-pricing priorities and was enabled by the administration’s most-favored-nation (MFN) pricing strategy, which aligns U.S. prices with international benchmarks.
The $100 billion commitment will fund U.S. research and development and capital investments, including manufacturing, over the next decade. AbbVie cited its roughly 29,000 U.S.-based employees and noted its products treat about 16 million Americans annually. The company positioned the pledge as a shift in its capital allocation and regulatory risk profile, balancing near-term margin pressures against longer-term capacity and innovation investments.
Robert A. Michael, AbbVie’s chairman and chief executive, said, "AbbVie is following President Trump's call to action by reaching this agreement, allowing us to collectively move beyond policies that harm American innovation."
